Munteanu Madalina Andreea, Swarnkar Surabhi, Popescu Razvan-Ionut, Lungu Anca, Ciobotaru Lucia, Nicolae Camelia, Tufanoiu Emil, Nanea Ioan Tiberiu
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"Prof. Dr. Th. Burghele" Clinical Hospital, Bucharest, Romania.
Maedica (Bucur). 2023 Mar;18(1):102-110. doi: 10.26574/maedica.2023.18.1.102.
Heart failure (HF) is a worldwide pandemic that affects at least 26 million people and is becoming more prevalent. Heart failure health expenditures are substantial and will considerably increase with population aging. Newer medications for treating type 2 diabetes include sodium-glucose cotransporter-2 inhibitors (SGLT2). Recent clinical studies and research have shown the efficacy of this class in treating heart failure by lowering the risk of cardiovascular events, hospitalization, and mortality. In addition, there is undeniable evidence that SGLT2 inhibitors have a beneficial effect on metabolic function, even though the mechanisms responsible for these drugs' practical consequences have not been completely elucidated. In this narrative review, we discuss the effects of SGLT2 inhibitors on the provision of cardiac energy by ketone bodies, pathological remodeling of the ventricle, arterial stiffness, and inflammation in patients with HF.
心力衰竭（HF）是一种全球性的流行病，影响着至少2600万人，且患病率正在上升。心力衰竭的医疗支出巨大，并且随着人口老龄化将大幅增加。治疗2型糖尿病的新型药物包括钠-葡萄糖协同转运蛋白2抑制剂（SGLT2）。最近的临床研究表明，这类药物通过降低心血管事件、住院和死亡风险，在治疗心力衰竭方面具有疗效。此外，有确凿证据表明SGLT2抑制剂对代谢功能有有益影响，尽管这些药物实际效果的作用机制尚未完全阐明。在这篇叙述性综述中，我们讨论了SGLT2抑制剂对心力衰竭患者酮体提供心肌能量、心室病理重塑、动脉僵硬度和炎症的影响。
